nach oben

nächster Artikel Histopathologic pitfalls of Mohs micrographic s...

Tipp

Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology

Zeitschrift:: Wiener Medizinische Wochenschrift > Ausgabe 9-10/2018

Autoren:: MD, PhD Assoc. Prof. Lyubomir A. Dourmishev, MD Dimitrina V. Guleva, MD, PhD Prof. Ljubka G. Miteva

Summary

Background

Connective tissue diseases are a heterogeneous group of autoimmune disorders affecting not only skin, but also various organs and systems. First-line treatment of connective tissue diseases is systemic steroids as monotherapy or combined with immunosuppressive drugs. Since intravenous immunoglobulins (IVIGs) have been found to be effective for various autoimmune dermatoses, their indications have expanded tremendously.

Objective

The aim this review article is to highlight the indications, effectiveness, and side effects of high doses immunoglobulins for treatment of patients with connective tissue diseases.

Methods

MEDLINE was searched for prospective clinical studies and case reports on IVIG treatment of lupus erythematosus, dermatomyositis, systemic sclerosis, and mixed connective tissue disease (MCTD). Included studies were analyzed and discussed in terms of the different disease entities.

Results and conclusion

IVIGs are a valuable alternative for treating therapy-resistant patients with lupus erythematosus, dermatomyositis, systemic sclerosis, or MCTD. However, more placebo-controlled clinical studies are needed to evaluate the exact indications and therapeutic regimens.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Bruton OC. Agammaglobulinemia. Pediatrics. 1952;16:722–8.

Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–31. CrossRefPubMed

Cherin P, Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs. 2010;24:211–23. CrossRefPubMed

Baleva M, Nikolov K. The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int J Rheumatol. 2011;2011:829751. CrossRefPubMedPubMedCentral

Nikolov K, Nikolova-Vlahova M, Baleva M. Side effects of intravenous immunoglobulins (IVIG). In: Allegro R, editor. Plasmopheresis and Immunoglobulins. New York: Nova; 2014. pp. 191–204.

Negi VS, Elluru S, Siberil S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27(3):233–45. CrossRefPubMed

Zhou C, Huang M, Xie L, et al. IVIG inhibits TNF-α-induced MMP9 expression and activity in monocytes by suppressing NF-κB and P38 MAPK activation. Int J Clin Exp Pathol. 2015;8(12):15879–86. PubMedPubMedCentral

Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2007;5(12):1124–37. CrossRefPubMed

Corvetta A, Della Bitta R, Gabrielli A, et al. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol. 1989;7(3):295–9. PubMed

10.

Boletis JN, Ioannidis JP, Boki KA, et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999;354:569–70. CrossRefPubMed

11.

Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum. 2000;29:321–7. CrossRefPubMed

12.

Costa N, Pires AE, Gabriel AM, et al. Broadened T‑cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T‑cells. J Clin Immunol. 2013;33(2):349–60. CrossRefPubMed

13.

Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat. 2004;15(1):46–50. CrossRefPubMed

14.

Piette JC, Frances C, Roy S, et al. High-dose immunoglobulins in the treatment of refractory kg/day for five consecutive days each month for a 12-cutaneous lupus erythematosus: open trial in 5 patients. Arthritis Rheum. 1995;38(Suppl 9):304.

15.

Espírito Santo J, Gomes MF, Gomes MJ, et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol. 2010;38(2–3):307–18. CrossRefPubMed

16.

Lampropoulos CE, Hughes GR. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol. 2007;26:981–3. CrossRefPubMed

17.

Généreau T, Chosidow O, Danel C, et al. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol. 1999;135(9):1124–5. CrossRefPubMed

18.

Kreuter A, Hyun J, Altmeyer P, et al. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2005;85(6):545–7. PubMed

19.

Brasileiro A, Fonseca Oliveira J, Pinheiro S, et al. Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin. Lupus. 2016;25(6):663–5. CrossRefPubMed

20.

Ky C, Swasdibutra B, Khademi S, et al. Efficacy of intravenous immunoglobulin Monotherapy in patients with cutaneous lupus Erythematosus: results of proof-of-concept study. Dermatol Reports. 2015;7(1):5804. CrossRefPubMedPubMedCentral

21.

De Pità O, Bellucci AM, Ruffelli M, et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus. 1997;6(4):415–7. CrossRefPubMed

22.

Cieza-Díaz DE, Avilés-Izquierdo JA, Ceballos-Rodríguez C, et al. Refractory subacute cutaneous lupus erythematosus treated with rituximab. Actas Dermosifiliogr. 2012;103(6):555–7. CrossRefPubMed

23.

Wollina U, Looks A, Kammler H‑J. Intravenous immunoglobulin therapy in dermatology: overview and center experience. An Bras Dermatol. 1998;73(3):255–9.

24.

Dourmishev LA, Dourmishev AL, Schwartz RA. Dermatomyositis: cutaneous manifestations of its variants. Int J Dermatol. 2002;41(10):625–30. CrossRefPubMed

25.

Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82. CrossRefPubMed

26.

Tansley S, Shaddick G, Christopher-Stine L, et al. Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. Clin Exp Rheumatol. 2016;34(5):880–4. PubMed

27.

Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729–35. CrossRefPubMedPubMedCentral

28.

Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000. CrossRefPubMed

29.

Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol. 1999;26(7):457–9. CrossRefPubMed

30.

Shahani L. Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin. BMJ Case Rep. 2012;18:2012.

31.

Amano H, Nagai Y, Katada K, et al. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. Br J Dermatol. 2007;156:1390–2. CrossRefPubMed

32.

Imataka G, Arisaka O. Long-term, high-dose intravenous immunoglobulin therapy in a patient with banker-type juvenile dermatomyositis. Cell Biochem Biophys. 2014;69(3):747–8. CrossRefPubMedPubMedCentral

33.

Speth F, Haas J‑P, Hinze CH. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatr Rheumatol Online J. 2016;14(1):52. CrossRefPubMedPubMedCentral

34.

Cafardi JM, Sami N. Intravenous immune globulin in Amyopathic Dermatomyositis – report of two cases and review of the literature. Open Rheumatol J. 2015;9:77–81. CrossRefPubMedPubMedCentral

35.

Wollina U, Looks A, Schneider R, et al. Disabling morphoea of childhood-beneficial effect of intravenous immunoglobulin therapy. Clin Exp Dermatol. 1998;23(6):292–3. CrossRefPubMed

36.

Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50(3):1005–7. CrossRefPubMed

37.

Asano Y, Ihn H, Asashima N, et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford). 2005;44(6):824–6. CrossRef

38.

Ihn H, Mimura Y, Yazawa N, et al. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol. 2007;156(5):1058–60. CrossRefPubMed

39.

Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):151–6. PubMed

40.

Szekanecz Z, Aleksza M, Antal-Szalmás P, et al. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects. Clin Rheumatol. 2009;28(3):347–50. CrossRefPubMed

41.

Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148–59. CrossRefPubMed

42.

Bodemer C, Teillac D, Le Bourgeois M, et al. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol. 1990;123(4):545–6. CrossRefPubMed

43.

Ulmer A, Kötter I, Pfaff A, et al. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J Am Acad Dermatol. 2002;46(1):123–7. CrossRefPubMed

44.

Matsuda M, Miki J, Oguchi K, et al. Fasciitis in mixed connective tissue disease successfully treated with high-dose intravenous immunoglobulin. Intern Med. 2003;42(9):910–1. CrossRefPubMed

45.

Rozin AP, Egozi D, Ramon Y, et al. Large leg ulcers due to autoimmune diseases. Med Sci Monit. 2011;17(1):CS1–7. CrossRefPubMedPubMedCentral

46.

Palabrica FR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac Allergy. 2013;3(4):249–56. CrossRefPubMedPubMedCentral

47.

Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87:206–18. PubMed

48.

Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223–6. CrossRefPubMed

49.

Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–62. CrossRefPubMed

50.

Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med. 1986;314:560–4. CrossRefPubMed

51.

Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin; A 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19(2):139–45. PubMed

52.

Krug P, Boyer O, Balzamo E, et al. Nephrotic syndrome in Kawasaki disease: a report of three cases. Pediatr Nephrol. 2012;27(9):1547–50. CrossRefPubMed

53.

Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 1997;20:1102–7. CrossRefPubMed

54.

Vecchietti G, Kerl K, Prins C, et al. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142(2):213–7. CrossRefPubMed

55.

Kurata M, Horie C, Kano Y, et al. Pompholyx as a clinical manifestation suggesting increased serum IgG levels in a patient with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Br J Dermatol. 2016;174(3):681–3. CrossRefPubMed

56.

Blackhouse G, Gaebel K, Xie F, et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc. 2010;8:14. CrossRefPubMedPubMedCentral

57.

Bamrungsawad N, Chaiyakunapruk N, Upakdee N, et al. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand. Pharmacoeconomics. 2015;33(5):521–31. CrossRefPubMed

Titel: Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology
Autoren:: MD, PhD Assoc. Prof. Lyubomir A. Dourmishev
MD Dimitrina V. Guleva
MD, PhD Prof. Ljubka G. Miteva
Publikationsdatum: 01.09.2017
DOI: https://doi.org/10.1007/s10354-017-0595-x
Verlag: Springer Vienna
Zeitschrift: Wiener Medizinische Wochenschrift
Ausgabe 9-10/2018
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Background

Objective

Methods

Results and conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9-10/2018

Comparative biomechanical analysis of three implants used in bicondylar tibial fractures

Psychosocial aspects associated with use of sunscreen, natural sunlight exposure, and artificial tanning

Mosaic capillaroscopic findings in systemic sclerosis

Histopathologic pitfalls of Mohs micrographic surgery and a review of tumor histology

Dog bite injury — alar repair with composite graft

Palmar hyperhidrosis treated by noninvasive ultrasound stellate ganglion block